| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.11. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 10.11. | Intelligent Bio Solutions GAAP EPS of -$0.86, revenue of $1.39M | 3 | Seeking Alpha | ||
| 10.11. | Intelligent Bio Solutions Inc. Q1 Loss Decreases | 2 | RTTNews | ||
| INTELLIGENT BIO SOLUTIONS Aktie jetzt für 0€ handeln | |||||
| 10.11. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Reports Record Fiscal First Quarter 2027 Revenue of $1.39 Million, Marking Sixth Consecutive Quarter of Year-Over-Year Growth | 2 | GlobeNewswire (USA) | ||
| 10.11. | INTELLIGENT BIO SOLUTIONS INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 21.10. | INTELLIGENT BIO SOLUTIONS INC. - 10-K/A, Annual Report | 8 | SEC Filings | ||
| 13.10. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 6 | SEC Filings | ||
| 11.09. | Intelligent Bio Solutions meldet höhere Aktienzahl nach Ausübung von Optionsscheinen | 2 | Investing.com Deutsch | ||
| 10.09. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions to Host Virtual Fireside Chat on September 24th at 4:30 p.m. ET | 2 | GlobeNewswire (USA) | ||
| 09.09. | Intelligent Bio Solutions submits FDA application for codeine test | 1 | Investing.com | ||
| 09.09. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | - | SEC Filings | ||
| 09.09. | Intelligent Bio Submits Comprehensive Clinical Data to Enter US Drug Screening Market | 2 | Benzinga.com | ||
| 09.09. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Submits FDA 510(k) Package for Intelligent Fingerprinting Drug Screening System, Seeking U.S. Market Clearance | 316 | GlobeNewswire (Europe) | NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing... ► Artikel lesen | |
| 04.09. | Intelligent Bio Solutions Secures Up To $15 Million Private Placement | 4 | pulse2.com | ||
| 01.09. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Achieves Above 98% Accuracy in Method Comparison Study, Supporting Planned 2026 FDA 510(k) Submission | 255 | GlobeNewswire (Europe) | NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing... ► Artikel lesen | |
| 28.08. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 20.08. | Intelligent Bio Solutions GAAP EPS of -$8.44, revenue of $4.22M | 5 | Seeking Alpha | ||
| 19.08. | INTELLIGENT BIO SOLUTIONS INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.08. | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth of 38% Year-over-Year, Driven by Reader Installed Base and High-Margin Cartridge Growth | 478 | GlobeNewswire (Europe) | Reader installed base grew 22% year-over-year, driving a 35% increase in total consumable cartridges to over 100,000 units Full year gross profit margin expanded to 48.63%, up 778 basis points year-over-year... ► Artikel lesen | |
| 19.08. | INTELLIGENT BIO SOLUTIONS INC. - 10-K, Annual Report | 3 | SEC Filings |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 14,980 | +0,74 % | EQS-News: Eckert & Ziegler SE: Bereinigtes EBIT im dritten Quartal +25%. Prognose 2026 bestätigt | EQS-News: Eckert & Ziegler SE
/ Schlagwort(e): 9-Monatszahlen
Eckert & Ziegler: Bereinigtes EBIT im dritten Quartal +25%. Prognose 2026 bestätigt
12.11.2026 / 07:45 CET/CEST
Für... ► Artikel lesen | |
| DRAEGERWERK | 119,00 | +6,63 % | EQS-News: Drägerwerk AG & Co. KGaA: Bekanntmachung nach Art. 5 Abs. 1 und Abs. 3 der Verordnung (EU) Nr. 596/2014: Erwerb eigener Aktien - Abschlussmeldung | EQS-News: Drägerwerk AG & Co. KGaA
/ Schlagwort(e): Sonstiges
Drägerwerk AG & Co. KGaA: Bekanntmachung nach Art. 5 Abs. 1 und Abs. 3 der Verordnung (EU) Nr. 596/2014: Erwerb eigener... ► Artikel lesen | |
| TELADOC HEALTH | 7,424 | +1,03 % | Truist raises Teladoc stock price target to $9 on EBITDA outlook | ||
| HIMS & HERS HEALTH | 15,570 | +0,19 % | Canaccord bekräftigt Kaufempfehlung für Hims & Hers nach Einführung von Peptid-Therapielinie | ||
| BICO GROUP | 1,462 | +0,69 % | BICO Group AB reports Q3 results | ||
| SERNOVA BIOTHERAPEUTICS | 0,066 | -1,50 % | Sernova Biotherapeutics-Aktie 19,8 % im Minus: 11,2 Millionen für die Fusion mit Seraxis | ||
| GERATHERM MEDICAL | 2,060 | -2,37 % | Geratherm Medical Aktie: Der Umbau soll die Wende bringen | Geratherm Medical steckt operativ weiter in einer schwierigen Phase. Im ersten Halbjahr 2026 sank der Umsatz um 12,5 Prozent auf 7,0 Millionen Euro, während das EBIT auf minus 0,5 Millionen Euro zurückging.... ► Artikel lesen | |
| ALIGN TECHNOLOGY | 149,00 | -0,30 % | Align Technology beruft zwei neue Mitglieder in den Verwaltungsrat | ||
| SYNLAB | - | - | EQS-News: SYNLAB: Synnovis and Apian partner to advance drone and autonomous robotics in healthcare logistics | EQS-News: SYNLAB
/ Key word(s): Miscellaneous
Synnovis and Apian partner to advance drone and autonomous robotics in healthcare logistics
07.09.2026 / 09:31 CET/CEST
The... ► Artikel lesen | |
| CERENOME | 0,474 | -27,04 % | Cerenome outlines $10M-$12.5M 2026 gross billings run rate exit while targeting mid-2027 REYOBIQ top line data | ||
| NUGEN MEDICAL DEVICES | 0,011 | -100,00 % | NuGen Medical Devices Inc.: NuGen Medical Devices Provides Update on Health Canada Licence Application | Toronto, Ontario--(Newsfile Corp. - November 13, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company"), a developer of needle-free drug delivery technology, provides an update regarding... ► Artikel lesen | |
| HEALWELL AI | 0,334 | +1,83 % | HEALWELL AI: HEALWELL More than Doubles YoY Adjusted EBITDA in Q3-2026 and Improves YTD Operating Cashflow by $26 Million | HEALWELL achieved revenue from continuing operations of $32.6 million in Q3-2026, an increase of 7% compared to revenue of $30.4 million in Q3-2025.HEALWELL reported positive Adjusted EBITDA1 of $1.6... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 1,680 | +1,20 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update | SEATTLE, Nov. 10, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other... ► Artikel lesen | |
| SPINEWAY | 0,089 | 0,00 % | Spineway: H1 2026 results | H1 2026 results Continued growth Stable resultsStrong embedded growth driversIssuance of straight bonds to finance future growth In thousands of eurosConsolidated financial statements - UnauditedH1... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | Sonoma Pharmaceuticals: Rekord bei Umsatz und Gewinn - lächerliche Bewertung! | Sonoma Pharmaceuticals macht den nächsten gewaltigen Schritt auf dem Weg zum profitablen Wachstumsunternehmen. Nach dem erstmaligen Erreichen eines positiven EBITDA im Vorquartal meldet der Healthcare-Spezialist... ► Artikel lesen |